Evidence map›Paper›PMID 35444708›Full record

ReviewClinical practice and epidemiology in mental health : CP & EMH2021

Health-Related Quality of Life Assessment in Patients with Myelodysplastic Syndromes: Evidence from Randomized Clinical Trials.

Johannes M Giesinger, Giorgio La Nasa, Francesco Sparano, Matthias Angermeyer, Emanuela Morelli, Olga Mulas, Fabio Efficace, Giovanni Caocci

Open access · diamondAbstract readReview
In one paragraph

Review in Clinical practice and epidemiology in mental health : CP & EMH, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed, 1 pooled it
1.2field-weighted citation impact, top 20% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 1 synthesis or guideline pooled it, 9 citations in OpenAlex.

  1. Pooled it
  2. Trial
  3. Article
  4. Review
  5. Article
  6. Myelodysplastic syndromes.Nature reviews. Disease primers · 2022
    Review
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 4 institutions in 2 countries.

Johannes M GiesingerMedical University of Innsbruck, University Hospital of Psychiatry II, Innsbruck, Austria.
Giorgio La NasaEmatologia e CTMO, Ospedale Businco, ARNAS "G. Brotzu", Cagliari, Italy.
Francesco SparanoItalian Group for Adult Hematologic Diseases (GIMEMA), Data Center and Health Outcomes Research Unit, Rome, Italy.
Matthias AngermeyerCenter for Public Mental Health, University of Vienna, Gosim am Wagram, Austria.
Emanuela MorelliEmatologia e CTMO, Ospedale Businco, ARNAS "G. Brotzu", Cagliari, Italy.
Olga MulasEmatologia e CTMO, Ospedale Businco, ARNAS "G. Brotzu", Cagliari, Italy.
Fabio EfficaceItalian Group for Adult Hematologic Diseases (GIMEMA), Data Center and Health Outcomes Research Unit, Rome, Italy.
Giovanni CaocciEmatologia e CTMO, Ospedale Businco, ARNAS "G. Brotzu", Cagliari, Italy.
Azienda Ospedaliera G. Brotzu · ITFondazione Gimema Onlus · ITUniversität Innsbruck · ATUniversity of Vienna · AT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Myelodysplastic syndromes (MDS) are characterized by ineffective hematopoiesis and blood cytopenia with a variable risk of progression to acute myeloid leukemia. The main goal of therapy for the large majority of patients is to improve health-related quality of life (HRQoL). Its rigorous assessment is now recommended in international MDS guidelines. Our review provides an overview of HRQoL results from randomized controlled trials (RCTs) in MDS patients. The literature search undertaken in PubMed identified 10 RCTs with HRQoL endpoints (all secondary) published between August 2008 and September 2020. These RCTs have helped to better understand the impact of therapies from the patient perspective and have generated valuable information that can be used to further support clinical decisions. However, the number of RCTs in MDS patients, including HRQoL endpoints, is still low. Given the importance of symptom relief and HRQoL improvement in the treatment of MDS patients, the assessment of the patient perspective in future RCTs is highly recommended to keep expanding the knowledge of the impact of new MDS therapies.

Indexed as

ErythropoietinHealth related quality of lifeHRQoLIPSSLenalidomideMyelodysplasia

Identifiers

PMID35444708
PMCPMC8985474
OpenAlexW4205422453

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.